The CEP89 antibody targets the centrosomal protein CEP89 (also known as LGALS or Galectin-3-binding protein), which plays a role in centrosome structure and function. CEP89 is a component of the centrosome, a critical organelle regulating cell division, microtubule organization, and cilia formation. The protein contains coiled-coil domains and interacts with other centrosomal proteins, contributing to centrosome maturation and stability. Research links CEP89 to cell cycle regulation, particularly during mitosis, and its dysfunction may disrupt centrosome duplication, leading to genomic instability or ciliopathies. Antibodies against CEP89 are widely used in studies to visualize centrosomal localization, assess protein expression levels, or investigate its role in diseases such as cancer or developmental disorders. These antibodies enable techniques like immunofluorescence, Western blotting, or immunoprecipitation, aiding in elucidating CEP89's molecular interactions and pathways. Recent studies also explore its potential as a biomarker or therapeutic target in tumors, where altered centrosome dynamics are common. Proper validation of CEP89 antibodies (e.g., specificity, species reactivity) is essential for experimental accuracy.